As the clock ticks toward the district court deadline for Sanofi and Regeneron Pharmaceuticals Inc. to withdraw Praluent (alirocumab) from the market, the two companies are trying to convince the US Court of Appeals for the Federal Circuit to stay the permanent injunction pending their appeal.
Their key argument is the public need for Praluent as an alternative to Amgen Inc.’s competing PCSK9 inhibitor Repatha...





